-
公开(公告)号:SG10201606462WA
公开(公告)日:2016-09-29
申请号:SG10201606462W
申请日:2010-09-23
Applicant: UCB PHARMA SA
Inventor: ELLIS MARK , HUMPHREYS DAVID PAUL
Abstract: A recombinant gram-negative bacterial cell comprising one or more of the following mutated protease genes: a. a mutated Tsp gene, wherein the mutated Tsp gene encodes a Tsp protein having reduced protease activity or is a knockout mutated Tsp gene; b. a mutated ptr gene, wherein the mutated ptr gene encodes a Protease III protein having reduced protease activity or is a knockout mutated ptr gene; and c. a mutated DegP gene encoding a DegP protein having chaperone activity and reduced protease activity ; wherein the cell is isogenic to a wild-type bacterial cell except for the mutated Tsp gene and/or mutated ptr gene and/or mutated Deg P gene and optionally a polynucleotide sequence encoding a protein of interest.
-
公开(公告)号:AU2010294905B2
公开(公告)日:2016-09-22
申请号:AU2010294905
申请日:2010-08-26
Applicant: UCB PHARMA SA
Inventor: NOVOTNEY-BARRY ANNA-MARIE , HULHOVEN REGINALD , PARKER GERALD L , HOSKIN VIOLET A
Abstract: The invention relates to the treatment of autoimmune or inflammatory disorders with antibodies to CD22. In particular, the invention relates to the treatment of autoimmune or inflammatory disorders with epratuzumab with a new dosing regimen. More particularly, the invention relates to the treatment of SLE.
-
公开(公告)号:MX341117B
公开(公告)日:2016-08-09
申请号:MX2012002907
申请日:2010-08-26
Applicant: UCB PHARMA SA
Inventor: ANNA-MARIE NOVOTNEY-BARRY , RÉGINALD HULHOVEN , GERALD L PARKER , VIOLET A HOSKIN
Abstract: La presente invención se refiere a un Epratuzumab para usarse en el tratamiento del lupus eritematoso sistémico (SLE), en donde epratuzumab está adaptado para ser administrable intravenosamente en una dosis particular fija de 600 mg una vez cada semana durante 4 veces a una dosis acumulada de 2400 mg de epratuzumab en un ciclo de tratamiento de 12 semanas, y en donde epratuzumab está adaptado para ser administrable en más de un ciclo de tratamiento de 12 semanas.
-
公开(公告)号:BR112013000623A2
公开(公告)日:2016-05-24
申请号:BR112013000623
申请日:2011-07-26
Applicant: UCB PHARMA SA
Abstract: purificação de proteína. a presente invenção diz respeito a um processo para a purificação de um fragmento de anticorpo a partir de um extrato de célula periplásmica que compreende uma primeira etapa de cromatografia de troca de cátion e uma segunda etapa de cromatografia de troca aniônica.
-
公开(公告)号:CL2014003283A1
公开(公告)日:2016-04-01
申请号:CL2014003283
申请日:2014-11-28
Applicant: UCB PHARMA SA
Inventor: YATES ANDREW JEFFREY , CLIPSTONE JAMES GREGORY
IPC: A61K39/395 , C07K16/28
-
公开(公告)号:TN2014000498A1
公开(公告)日:2016-03-30
申请号:TN2014000498
申请日:2014-11-28
Applicant: UCB PHARMA SA
Inventor: YATES ANDREW JEFFREY , CLIPSTONE JAMES GREGORY
IPC: C07K16/28
-
公开(公告)号:AU2016201536A1
公开(公告)日:2016-03-24
申请号:AU2016201536
申请日:2016-03-09
Applicant: UCB PHARMA SA
Inventor: ELLIS MARK , HUMPHREYS DAVID PAUL
Abstract: A recombinant gram-negative bacterial cell comprising one or more of the following mutated protease genes: a. a mutated Tsp gene, wherein the mutated Tsp gene encodes a Tsp protein having reduced protease activity or is a knockout mutated Tsp gene; b. a mutated ptr gene, wherein the mutated ptr gene encodes a Protease III protein having reduced protease activity or is a knockout mutated ptr gene; and c. a mutated DegP gene encoding a DegP protein having chaperone activity and reduced protease activity ; wherein the cell is isogenic to a wild-type bacterial cell except for the mutated Tsp gene and/or mutated ptr gene and/or mutated Deg P gene and optionally a polynucleotide sequence encoding a protein of interest. 7493670_1 (GHMatters) P89876.AU.1
-
">
公开(公告)号:BRPI1006160A2
公开(公告)日:2016-02-23
申请号:BRPI1006160
申请日:2010-01-12
Applicant: UCB PHARMA SA
Inventor: LAWSON ALASTAIR DAVID GRIFFITHS
IPC: G01N33/68
-
公开(公告)号:MA37619A1
公开(公告)日:2016-01-29
申请号:MA37619
申请日:2013-05-13
Applicant: UCB PHARMA SA
Inventor: FINNEY HELENE MARGARET , LAWSON ALASTAIR DAVID GRIFFITHS , SHAW STEVAN GRAHAM , SMITH BRYAN JOHN , TYSON KERRY LOUISE , KEVORKIAN LARA , MEIER CHRISTOPH , SARKAR KAUSHIK , ATHERFOLD PAUL ALAN
Abstract: L'invention concerne des anticorps spécifiques de fcrn, des formulations les comprenant, l'utilisation de chacun en thérapie, des procédés d'expression et facultativement de formulations dudit anticorps, de l'adn codant pour les anticorps et des hôtes comprenant ledit adn..
-
公开(公告)号:CA2747396C
公开(公告)日:2015-12-08
申请号:CA2747396
申请日:2010-01-27
Applicant: UCB PHARMA SA
Inventor: CUYPERS SERGE , BERWAER MONIQUE , FANARA DOMENICO , BARILLARO VALERY , LARBANOIX MARTINE , DARGELAS FREDERIC
IPC: A61K9/20 , A61K31/4015
Abstract: The present invention relates to an immediate release formulation of pharmaceutical compounds.
-
-
-
-
-
-
-
-
-